✦ LIBER ✦

Intravenous, non-viral RNAi gene therapy of brain cancer

✍ Scribed by Pardridge, William M

Book ID: 121868252
Publisher: Informa plc
Year: 2004
Tongue: English
Weight: 215 KB
Volume: 4
Category: Article
ISSN: 5847-4714
DOI: 10.1517/14712598.4.7.1103

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Blood–brain Barrier Transport of Non-vir

Blood–brain Barrier Transport of Non-viral Gene and RNAi Therapeutics

✍ Ruben J. Boado 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 775 KB

Non-viral cancer gene therapy: Beyond de

Non-viral cancer gene therapy: Beyond delivery

✍ Akhtar, S 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 88 KB

Non-viral cancer gene therapy – what is

Non-viral cancer gene therapy – what is best? ▾

✍ Manfred Ogris 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Pharmacokinetic considerations regarding

Pharmacokinetic considerations regarding non-viral cancer gene therapy

✍ Makiya Nishikawa; Yoshinobu Takakura; Mitsuru Hashida 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 264 KB

Lysosomal Enzyme Replacement of the Brai

Lysosomal Enzyme Replacement of the Brain with Intravenous Non-Viral Gene Transfer

✍ Yun Zhang; Yuntao Wang; Ruben J. Boado; William M. Pardridge 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 156 KB

In vivo knockdown of gene expression in

In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats

✍ Yun Zhang; Ruben J. Boado; William M. Pardridge 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB

## Abstract ## Background Gene silencing in mammalian cells is possible with RNA interference (RNAi) with expression plasmids that encode for short hairpin RNAs (shRNA) that hybridize to a specific sequence within a target mRNA. The limiting factor in developing RNAi therapeutics in mammals is the